An overview of studies looking at the potential of osteoclast inhibitors in the prevention of breast cancer recurrences in the adjuvant setting.
It is important for oncologists to monitor, design, and administer appropriate bone health treatments at the earliest stages for the 80% to 90% of patients with multiple myeloma who develop osteolytic bone lesions.
The nonsteroidal anti-inflammatory drug naproxen significantly decreases the incidence, severity, and duration of pegfilgrastim-induced bone pain in patients diagnosed with a nonmyeloid cancer.
Spurred by the desire to provide the full spectrum of care to prostate cancer patients, urologists across the country have begun to integrate bone health clinics into their practices.
Monitoring bone health and ensuring adequate calcium and vitamin D intake in postmenopausal women who are taking exemestane for the primary prevention of breast cancer is essential.
Targeting the bone microenvironment appears to be a potential approach to treating prostate cancer.
While pertuzumab is moving ahead in the FDA approval process, an additional indication for denosumab might be halted.
Upfront zoledronic acid is superior to delayed use in postmenopausal women with early breast cancer who are being treated with the aromatase inhibitor letrozole.
Antiresorptive medicines used to reduce the loss of bone mass related to bone metastases or treatment toxicity are associated with an increased risk of ONJ.
Bone disease occurs in about 84% of patients with multiple myeloma and is responsible for a great deal of morbidity, including pain, hypercalcemia, compromised quality of life, and pathological fracture.